Navigation Links
HIV vaccine trial breaks ground for future research

The results of the world's first phase 3 HIV vaccine efficacy trial are reported in the March 1 issue of The Journal of Infectious Diseases, now available online. Although the vaccine was ineffective in preventing HIV infection, the trial represents a landmark in the fight against HIV and offers the scientific community a foundation on which to build future trials.

The multi-centered trial, conducted in the United States and the Netherlands and completed in 2003, is described in two papers by the rgp120 HIV Vaccine Study Group, and Peter B. Gilbert and colleagues, which address the vaccine efficacy results and the immunologic responses of the study participants.

The vaccine, produced by VaxGen, was a recombinant construct of the HIV envelope glycoprotein, similar to the type of vaccine used to develop a vaccine for hepatitis B. The vaccine was tested in a double-blind, randomized study of healthy participants who did not use intravenous drugs. The volunteers were men who have sex with men or women at high risk for heterosexual transmission. The vaccine and placebo were given by injection seven times over 30 months and the participants were assessed for risk. At each visit the participants were tested for HIV infection, and for those who were positive, HIV-1 plasma RNA load and CD4 cell counts were monitored on a regular basis for 24 months after the initial diagnosis.

Of the 5,417 volunteers who were enrolled, 368 became infected during the study. The vaccine was found not to be effective in preventing HIV infection; infection rates among those who were given the vaccine and those who were given placebo were 6.7 percent and 7.0 percent, respectively. Of those who became infected during the study, pre-treatment viral loads were similar in the placebo and vaccine groups over their follow-up visits.

During analysis of various subgroups of the study population, a higher, though statistically insignificant, vaccine efficacy was found in the high-risk and the non-white groups. The authors suggested two plausible explanations, one for each group. Those with high-risk behavior may have been exposed frequently to HIV and a primed immune response, probably cellular or humoral, could have worked with the vaccine and caused a greater ability to resist the virus. For the non-white group, the authors suggest that biological differences in immune response or genetic markers of resistance to infection could have made the vaccine more effective.

Also examined in the trial were the immune responses to the vaccine. The vaccine was able to generate antibody responses in virtually all participants, and, in general, those with a higher response had a lower rate of infection than the placebo group. In an editorial accompanying the two papers, Barney Graham and John Mascola of the Vaccine Research Center of the National Institutes for Health commented that more research is needed to be sure whether a high vaccine antibody response is related to a lower incidence of HIV infection. Citing the possible slight vaccine efficacy for non-white and high-risk participants of the trial, they urged that future vaccines be studied in a wide range of racial, ethnic, and diverse risk-level groups. They concluded that the landmark study will inform future studies, and an HIV vaccine will be found only through robust public and private investment as well as a well-informed public and scientific community.


'"/>

Source:Infectious Diseases Society of America


Related biology news :

1. Research advances quest for HIV-1 vaccine
2. A much-needed shot in the arm for HIV vaccine development
3. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
4. Gene vaccine for Alzheimers disease shows promising results
5. Influenza vaccine uses insect cells to speed development
6. Norovirus, AIDS vaccine and Hepatitis Virus
7. Live vaccines more effective against horse herpes virus
8. NIAID begins clinical trial of West Nile virus vaccine
9. Designing vaccines by computer
10. Wake Forest scientists find new combination vaccine effective against plague
11. New vaccine means bye-bye to bacteria in the lung
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/20/2016)... LONDON , Dec. 20, 2016 ... car sharing, rental and leasing is stoking significant ... of radio frequency technology, Bluetooth low energy (BLE), ... emerge as the next wave of wireless technologies ... vehicle access system to advanced access systems opens ...
(Date:12/19/2016)... y TORONTO , 19 de diciembre de 2016 ... Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado ... tipos de tumor en 2017, con múltiples sitios previstos a lo ... ... objetivo en el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica ...
(Date:12/16/2016)... , Dec 16, 2016 Research and ... System Market - Global Forecast to 2021" report to their ... The ... to grow at a CAGR of 14.06% from 2016 to 2021. ... and is projected to reach 854.8 Million by 2021. The growth ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... OR (PRWEB) , ... January 18, 2017 , ... ... that provide essential device-to-computer interconnect using USB or PCI Express, announced the ZEM5310 ... Cyclone V E FPGA into a compact business-card sized form factor suitable for ...
(Date:1/18/2017)... Jan. 18, 2017 Applied BioMath ( ... to drug research and development, today announced that ... and CEO of Applied BioMath, will present at ... Modeling (BAGIM) Meeting on Thursday January 19, 2017 ... , MA.   Dr. Burke,s talk "Quantitative Modeling ...
(Date:1/18/2017)... ... January 18, 2017 , ... Total ... successfully implanted SpineFrontier’s A-CIFT™ Solofuse-P™. The operation took place on Wednesday, January 11, ... The procedure was an anterior cervical discectomy and fusion on a 42 year ...
(Date:1/18/2017)... ... January 18, 2017 , ... MYOLYN, ... that it has submitted a 510(k) to the FDA, requesting clearance of the ... functional electrical stimulation (FES) technology. , The submission marks a major milestone ...
Breaking Biology Technology: